Português The use of cannabidiol as a treatment for autism
DOI:
https://doi.org/10.5281/zenodo.7858939Keywords:
Cannabidiol, Autistic Spectrum Disorder, TEA, CBD, TreatmentAbstract
This study aimed to analyze the benefit of using cannabidiol as a treatment in people with autism spectrum disorder, analyzing its effect on comorbidities and symptoms present on the spectrum. This is an integrative review with descriptive analysis on autism, its comorbidities, the use of cannabis components and CBD as a form of treatment for ASD. As a theoretical reference for the review, 19 studies from the main scientific article platforms were used. Through the study, the main comorbidities that affect autistic people were evidenced, being psychiatric, clinical signs and developmental delay such as intellectual impairment, anxiety, depression, attention deficit disorder with hyperactivity, obsessive-compulsive disorder, sleep disturbance, constipation and reflux , food selectivity, seizures and epilepsy. In pharmacological intervention, several drugs are used for each comorbidity, increasing the amount of drugs prescribed for ASD patients. Tests carried out with CBD showed its wide use as an anxiolytic and antipsychotic, in addition to resulting in behavioral and social improvements, covering several symptoms of autism and having mild side effects. It is concluded that cannabidiol proves to be a promising drug to treat the comorbidities and symptoms present in autism, however more specific studies are still needed to ensure CBD in relation to its prolonged use in autistic.
Downloads
References
AISHWORIYA, Ramkumar et al. An Update on Psychopharmacological Treatment of Autism Spectrum Disorder. Neurotherapeutics, 2022. 248-262 p. v. 19.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-5. 5. ed. Washington, DC: American Psychiatric Association, 2013.
ARAN, Adi et al. Cannabinoid treatment for autism: a proof-of-concept randomized trial. Molecular autism, 2021. v. 12.
BARROS NETO, Sebastião Gonçalves De; BRUNONI, Decio; CYSNEIROS, Roberta Monterazzo. Abordagem psicofarmacológica no transtorno do espectro autista: uma revisão narrativa. 2. ed. Local: Distúrb. Desenvolv., 2019. 38-60 p. v. 19.
BRASIL. Lei nº 12.764, de 27 de dezembro de 2012. Política Nacional de Proteção dos Direitos da Pessoa com Transtornos do Espectro Autista. Brasília, DF: Presidência da República, Casa Civil, 2012.
BRASIL. Lei nº 13.977 de 08 de janeiro de 2020. Carteira de Identificação da Pessoa com Transtorno do Espectro Autista (Ciptea). Brasília, DF: Presidência da República, Casa Civil, 2020.
CAMARGO FILHO, Marcelo Ferrari De Almeida et al. Canabinoides como uma nova opção terapêutica nas doenças de Parkinson e de Alzheimer: uma revisão de literatura. 2. ed. Rev Bras Neurol, 2019. 17-32 p. v. 55.
FOMBONNE, Eric. Epidemiological Surveys of Autism and Other Pervasive Developmental Disorders: An Update. Journal of Autism and Developmental Disorders, 2003. 365–382 p. v. 33.
FOMBONNE, Eric. Epidemiology of pervasive developmental disorders. Pediatr Res, 2009. 591-598 p.
HOLDMAN, Richard et al. Safety and Efficacy of Medical Cannabis in Autism Spectrum Disorder Compared with Commonly Used Medications. Cannabis Cannabinoid, 2022. 451-463 p. v. 7.
KLUMPERS, Linda E; THACKER, David L. A Brief Background on Cannabis: From Plant to Medical Indications. Journal of AOAC International, 2019. 412–420 p. v. 102.
LEVY, Susan E; MANDELL, David S; SCHULTZ, Robert T. Autism. Lancet, 2009.
LI, Qian et al. Prevalence of Autism Spectrum Disorder Among Children and Adolescents in the United States From 2019 to 2020. 9. ed. LAMA Pediatr, 2022. 943-945 p. v. 176.
LOPES, Ana Maria Costa Da Silva et al. O autismo e suas conexões: qual medicação para o autista?. 3. ed. Belo Horizonte: Psicol. rev, 2019. 1343-1352 p. v. 25.
LORD, Catherine et al. Autism spectrum disorder. Lancet, 2018. 508-520 p. v. 392.
MAENNER, Matthew J. et al. Prevalence and Characteristics of Autism Spectrum Disorder Among Children Aged 8 Years: Autism and Developmental Disabilities Monitoring Network, 11 Sites, United States, 2018. 11. ed. Lolecular autism, 2021. 1-16 p. v. 70.
MALIK, Fatima; MARWAHA, Raman. Cognitive Development. StatPearls, 2022.
MATOS, Rafaella L. A. et al. O Uso do Canabidiol no Tratamento da Epilepsia. 2. ed. Local: Rev. Virtual Quim, 2017. 786-814 p. v. 9.
POLEG, Shani et al. Cannabidiol as a suggested candidate for treatment of autism spectrum disorder. Progress in neuro-psychopharmacology & biological psychiatry, 2018. 90-96 p. v. 89.
SHAW, Kelly A et al. Early Identification of Autism Spectrum Disorder Among Children Aged 4 Years: Autism and Developmental Disabilities Monitoring Network, 11 Sites, United States, 2018. Washington, DC: MMWR Surveill Summ, 2021. 1-14 p. v. 70.
SILVA, Micheline; MULICK, James A. Diagnosticando o transtorno autista: aspectos fundamentais e considerações práticas. 1. ed. Lsicol. cienc. prof. [online], 2009. 116-131 p. v. 29.
ZWAIGENBAUM, Lonnie et al. Early Intervention for Children With Autism Spectrum Disorder Under 3 Years of Age: Recommendations for Practice and Research. Pediatrics, 2015. 60-81 p. v. 136.
